2018
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study
Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, Ballman KV, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, Hurria A. Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Research And Treatment 2018, 171: 325-334. PMID: 29789969, PMCID: PMC6076849, DOI: 10.1007/s10549-018-4828-5.Peer-Reviewed Original ResearchConceptsHormone receptor-positive advanced breast cancerAdvanced breast cancerIncidence of gradeAdverse eventsBreast cancerPhysical functionProgression-free survival benefitMultivariable logistic regression modelAddition of bevacizumabPhase III trialsPhysical function measuresAdverse event dataFunctional Assessment MeasureIncidence of toxicityFlight of stairsLogistic regression modelsHemorrhagic eventsIII trialsSurvival benefitMedian ageThrombosis eventsRisk factorsUnivariate analysisAssessment measuresBevacizumab
2016
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research 2016, 22: 3764-3773. PMID: 26957554, PMCID: PMC6773427, DOI: 10.1158/1078-0432.ccr-15-2477.Peer-Reviewed Original Research
2013
Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343
Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343. Journal Of Clinical Oncology 2013, 31: 2382-2387. PMID: 23690420, PMCID: PMC3691356, DOI: 10.1200/jco.2012.45.2615.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Agents, HormonalBiomarkers, TumorBreast NeoplasmsFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMastectomy, SegmentalNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioRadiotherapy, AdjuvantReceptors, EstrogenTamoxifenTime FactorsTreatment OutcomeConceptsBreast cancer-specific survivalEarly-stage breast cancerCancer-specific survivalOverall survivalBreast cancerRadiation therapyRegional recurrenceDistant metastasisER-positive early-stage breast cancerDistant disease-free survivalWomen age 70 yearsEstrogen receptor-positive breast carcinomasFrequency of mastectomyTen-year OSAdjuvant radiation therapyPrimary end pointDisease-free survivalEarly breast cancerAge 70 yearsBreast-conserving surgeryBreast preservationCALGB 9343Locoregional recurrenceTAM groupLocal recurrence
2012
The Effect of Age on Delay in Diagnosis and Stage of Breast Cancer
Partridge AH, Hughes ME, Ottesen RA, Wong Y, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Tamimi RM. The Effect of Age on Delay in Diagnosis and Stage of Breast Cancer. The Oncologist 2012, 17: 775-782. PMID: 22554997, PMCID: PMC3380876, DOI: 10.1634/theoncologist.2011-0469.Peer-Reviewed Original ResearchConceptsHigher stage diseaseBreast cancerYoung womenStage diseaseNational Comprehensive Cancer Network centersInitial signsYounger ageHigher stageBreast cancer diagnosisAdvanced diseaseEffect of ageIndependent predictorsSymptomatic diseaseStage ICancerDiagnosisDiseaseSymptomsCancer diagnosisWomenOlder counterpartsAgeSimilar adjustmentSignsDays
2010
Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer
Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, Edge S, Shapiro CL, Dressler L, Paskett E, Kimmick G, Orcutt J, Scalzo A, Winer E, Levine E, Shahab N, Berliner N, B F. Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer. Journal Of The National Cancer Institute 2010, 102: 942-949. PMID: 20554945, PMCID: PMC2897879, DOI: 10.1093/jnci/djq211.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Agents, HormonalBreast NeoplasmsCase-Control StudiesChemotherapy, AdjuvantEstrogen Receptor ModulatorsFactor VFemaleHumansLogistic ModelsMiddle AgedMultivariate AnalysisMutationOdds RatioPrevalenceRisk FactorsSelective Estrogen Receptor ModulatorsSmokingTamoxifenThromboembolismConceptsFactor V LeidenEarly-stage breast cancerThromboembolic eventsAdjuvant tamoxifenFVL mutationBreast cancerTamoxifen useTE riskControl subjectsOdds ratioFactor V Leiden mutationCase-control studyConditional logistic regressionV Leiden mutationPostmenopausal womenThromboembolism riskThrombosis riskMultivariable modelTherapeutic decisionsV LeidenLeiden mutationHigh riskPositive testTamoxifenCancer
2008
Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis
Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis. Journal Of The National Cancer Institute 2008, 100: 642-648. PMID: 18445827, PMCID: PMC2864146, DOI: 10.1093/jnci/djn100.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Agents, HormonalAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantCytochrome P-450 CYP2D6Decision Support TechniquesDisease-Free SurvivalEstrogen Receptor ModulatorsFemaleGenotypeHumansMarkov ChainsMiddle AgedMutationNeoplasms, Hormone-DependentOdds RatioPostmenopauseReceptors, EstrogenSelective Estrogen Receptor ModulatorsTamoxifenConceptsDisease-free survivalWt/wt patientsAromatase inhibitorsBreast cancerCYP2D6 genotypeEndocrine therapyWT patientsNorth Central Cancer Treatment Group trialsEstrogen receptor-positive breast cancerBreast International Group (BIG) 1Optimal adjuvant endocrine therapyReceptor-positive breast cancerDisease-free survival outcomesAromatase inhibitor monotherapyAdjuvant endocrine therapyAdjuvant endocrine treatmentPostmenopausal breast cancerActive tamoxifen metabolitesBreast cancer patientsCytochrome P450 2D6Adjuvant tamoxifenEndocrine treatmentPostmenopausal womenHazard ratioInhibitor monotherapyRisk Perceptions and Psychosocial Outcomes of Women With Ductal Carcinoma In Situ: Longitudinal Results From a Cohort Study
Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E. Risk Perceptions and Psychosocial Outcomes of Women With Ductal Carcinoma In Situ: Longitudinal Results From a Cohort Study. Journal Of The National Cancer Institute 2008, 100: 243-251. PMID: 18270338, DOI: 10.1093/jnci/djn010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnxietyBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingCohort StudiesDepressionFemaleHumansLogistic ModelsLongitudinal StudiesMammographyMass ScreeningMassachusettsMiddle AgedNeoplasm Recurrence, LocalOdds RatioPredictive Value of TestsPrognosisQuality of LifeRisk AssessmentRisk FactorsConceptsLocal recurrence rateRecurrence ratePsychosocial outcomesDuctal carcinomaModerate riskCancer-related risksFavorable overall prognosisSystemic recurrence ratesBreast-conserving treatmentBreast cancer riskDCIS diagnosisCohort studyDCIS recurrenceOverall prognosisDisease recurrenceInvasive cancerDCISCancer riskPsychosocial concernsHealth behaviorsEnrollment surveySubstantial anxietyWomenInaccurate perceptionsModerate likelihood
2007
Surveillance Testing Among Survivors of Early-Stage Breast Cancer
Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Surveillance Testing Among Survivors of Early-Stage Breast Cancer. Journal Of Clinical Oncology 2007, 25: 1074-1081. PMID: 17369571, DOI: 10.1200/jco.2006.08.6876.Peer-Reviewed Original ResearchMeSH KeywordsAgedBreast NeoplasmsCohort StudiesDiagnostic Tests, RoutineFemaleFollow-Up StudiesGuideline AdherenceHumansLogistic ModelsLong-Term CareMedical OncologyNeoplasm StagingOdds RatioOffice VisitsPopulation SurveillancePractice Guidelines as TopicPractice Patterns, Physicians'Primary Health CareSEER ProgramSurvivorsTime FactorsUnited StatesUnnecessary ProceduresConceptsBreast cancer survivorsChest X-rayMedical oncologistsCancer survivorsBreast cancerAbdominal imagingAntigen testingBone scanStage I/II breast cancerEarly-stage breast cancer patientsMost breast cancer survivorsEnd Results-Medicare dataSurveillance testingEarly-stage breast cancerRepeated-measures logistic regressionBreast cancer patientsLow-risk populationPopulation-based cohortTypes of physiciansRoutine surveillance testingRate of testingAntigen testCancer patientsWomen's ageSurveillance years
2006
The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer
Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer. Cancer 2006, 106: 2576-2582. PMID: 16703595, DOI: 10.1002/cncr.21919.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantCross-Over StudiesDecision Support TechniquesDisease-Free SurvivalDrug Administration ScheduleFemaleHumansMarkov ChainsMiddle AgedModels, StatisticalModels, TheoreticalNeoplasm StagingOdds RatioPostmenopauseRandomized Controlled Trials as TopicReceptors, ProgesteroneTamoxifenTime FactorsTreatment OutcomeConceptsDisease-free survivalAromatase inhibitorsProgesterone receptorEstrogen receptorOptimal adjuvant endocrine therapyEarly-stage breast cancerAdjuvant endocrine therapyNode-positive groupProgesterone receptor statusRandomized clinical trialsSequential treatmentBreast cancer tumorsAI monotherapyAI therapyBiologic subsetsDFS ratesAdjuvant therapyEndocrine therapyPostmenopausal patientsPostmenopausal womenSequential therapyUpfront treatmentLymph nodesReceptor statusPR expression
1997
Probability of Carrying a Mutation of Breast-Ovarian Cancer Gene BRCA1 Based on Family History
Berry D, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of Carrying a Mutation of Breast-Ovarian Cancer Gene BRCA1 Based on Family History. Journal Of The National Cancer Institute 1997, 89: 227-237. PMID: 9017003, DOI: 10.1093/jnci/89.3.227.Peer-Reviewed Original Research